Mumbai, Aug. 21 -- The products are bioequivalent and therapeutically equivalent to the reference drug marketed by Fresenius Kabi.

According to IQVIA data, the combined US market for Calcium Gluconate Injection for all these strengths was worth approximately $69.9 million in the 12 months ended June 2026.

Calcium gluconate injection is primarily used for the treatment of acute symptomatic hypocalcemia.

Marc Kikuchi, president & business head, North America, said: "The launch of Calcium Gluconate Injection USP marks another important step in strengthening Glenmark's U.S. injectables business and expanding our hospital portfolio.

It reflects the disciplined execution of our strategy to build a differentiated and sustainable injectables ...